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According to the classification criteria of antiphospholipid syndrome (APS), lupus anticoagulant (LA), anticardiolipin 
(aCL) and anti-β2-glycoprotein I antibody (aβ2GPI)assays are independent risk factors for the occurrence of vascular 
thrombosis and pregnancy loss.1 It is generally accepted that patients carrying multiple positivity for antiphospholipid 
(aPL) antibodies have a more severe disease and higher recurrence rate despite treatment. On the other hand, the stable 
positivity of a single test is sufficient to classify a patient as having APS.2 As a consequence, clinicians have been 
wondering whether patients with similar clinical features, but with different positivity patterns (profiles) in the three 
aPL tests, should be considered completely comparable or not. 
We retrospectively studied 3088 consecutive patients who were referred within a 24-month period (January 2007 to 
January 2009) to coagulation laboratory for the following indications: (A) suspected thrombophilia (thrombotic 
diathesis), (B) suspected obstetric APS, (C) unexplained prolonged clotting time, (D) other haemostatic problems if a 
prolonged and inhibited phospholipid-dependent clotting time was found, (E) screening in co-existent autoimmune 
disease. LA, aCL (ELISA kit, Phadia, EliA Cardiolipin IgG/IgM, Uppsala, Sweden) and aβ2GPI (ELISA kit, Phadia, 
EliA ß2GliocproteinI IgG/IgM) were searched in all the 3088 patients. LA measurement included four tests: dilute 
Russell's viper venom time (dRVVT, Hemosil, LA-screen/confirm, Instrumentation Laboratory, Lexington, 
Massachusetts, USA), partial thromboplastin time-LA (PTT-LA; Diagnostica Stago, Asnieres, France), silica clotting 
time (HemosIL; DiaPharma Group, Ohio, USA) and kaoline clotting time (homemade, according to Exner).3 If PTT-LA 
was prolonged, the hexagonal phospholipid neutralisation test was performed as a confirmation (STACLOT-LA, 
Diagnostica Stago). In 200 subjects (6.5%), LA was positive on two occasions; and of these, 72 (36%) patients were 
diagnosed as having APS, according to the revised criteria.2 In 425 subjects (13.8%), aPL (aCL and /or aβ2GPI, 
detected according to current criteria 2) were present in two occasions, in the absence of LA; and of these only 4 (0.9%) 
were diagnosed as having APS. Details are shown in table 1. 
Using these data, we set-up a risk model for APS diagnosis based on aPL positivity, their titre and methods used for LA 
research. Estimates for the probability of APS diagnosis were derived from logistic regression equations. The resulting 
chart (figure 1) shows that multiple aPL positivity, particularly the triple association of LA, aCL and aβ2GPI, increases 
the risk of APS. Among the aPL, LA is more strongly associated with the diagnosis of APS, particularly if detected with 
PTT-LA/STACLOT-LA or dRVVT. Interestingly, multiple positivity for different LA tests is not associated with a 
higher risk. Besides, the risk is estimated as ranging from low risk to high risk, according to subclassification of 
subjects based on aCL and aβ2GPI titres (as defined in figure 1). These data suggest a substantial improvement in risk 
prediction of APS diagnosis based on the assessment of the aPL profile, having the advantage of the quantification of 
such a risk by APS risk scale. From a speculative point of view, such an approach on the subclassification of patients 
based upon different combinations of positive tests may in future influence not only the prognostic judgment but also, 
more critically, the pharmacological treatment. 
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Table 1 
Epidemiologic, clinical and serologic characteristic of the subjects enrolled in the study 
Subjects N. 
Male/female 789/2299 (22.5 / 74.5 % of the total subjects) 
Male/female with aPL positivity 64/561 
Mean age 49.2 years (17–85) 
LA positivity 200 (6.5% of the total subjects) 
LA positivity alone 78 (2.5% of the total subjects) 
aCL and/or aβ2GPI positivity, negative LA 425 (13.8% of the total subjects) 
APS 76 (12.16% of aPL-positive patients) 
Vascular APS 56 
Obstetric APS 17 
Vascular associated with obstetric APS 3 
Primary APS 32 
APS with positive LA 72 (36% of LA-positive patients) 
APS with positive LA alone 28 (14% of LA-positive patients) 
APS in aCL- and/or aβ2GPI-positive patients with LA negative 4 (0.9% of aCL- and/or aβ2GPI-positive patients) 
 
APS diagnosed according to the revised criteria. Vascular APS refers to venous and arterial thrombotic events. 
Obstetric APS refers to (A) one or more unexplained deaths of a morphologically normal fetus at or beyond the 10th 
week of gestation; (B) one or more premature births of a morphologically normal neonate before the 34th week of 
gestation because of (1) eclampsia or severe pre-eclampsia defined according to standard definitions or (2) recognised 
features of placental insufficiency; (C) three or more unexplained consecutive spontaneous abortions before the 10th 
week of gestation, with maternal chromosomal causes excluded. 
aβ2GPI, anti-β2-glycoprotein I; aCL, anticardiolipin; aPL, antiphospholipid; APS, antiphospholipid syndrome;.LA, 
lupus anticoagulant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Risk model for antiphospholipid syndrome (APS) diagnosis based on antiphospholipid (aPL) positivity, their 
titre and methods used for lupus anticoagulant (LA) research. (A) APS risk is estimated according to aPL 
profile, showing that each further positivity increases the risk of APS diagnosis. Multiple aPL positivity, 
particularly the triple association of LA, anticardiolipin (aCL) and aβ2GPI, further increases the risk of APS. 
(B) Chart for the risk of APS shows risk ranging from low to high risk based on aPL (aCL and aβ2GPI) titres 
and methods for LA research (dRVVT, PTT-LA/STACLOT-LA, SCT, KCT). In our experience, a titre of 30 
U/litre represents a value ≥99 percentile (according to current criteria), thus we set this cut-off value to 
determinate moderate aCL and aβ2GPI positivity. The 50 U/litre as cut-off value for high titre was set 
arbitrarily. The highest aCL or aβ2GPI isotype was used in the analyses. aPL, antiphospholipid; aCL, 
anticardiolipin; LA, lupus anticoagulant; aβ2GPI, anti-β2-glycoprotein I antibody; dRVVT, dilute Russell's 
viper venom time; PTT-LA, partial thromboplastin time-LA; SCT, silica clotting time; KCT, kaoline clotting 
time. 
 
